Treatment with propranolol for infantile hemangiomas: A case series of 106 infants

Li,Shang‑Bin; Xu,Guang‑Qi; Gao,Feng; Huo,Ran

doi:10.3892/etm.2015.2485

Treatment with propranolol for infantile hemangiomas: A case series of 106 infants

Authors:
- Shang‑Bin Li
- Guang‑Qi Xu
- Feng Gao
- Ran Huo
View Affiliations

Affiliations: Department of Aesthetic, Plastic and Burn Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: May 8, 2015 https://doi.org/10.3892/etm.2015.2485
Pages: 51-54
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the clinical benefit and side effects of propranolol treatment in 106 children with infantile hemangiomas (IHs). A retrospective chart review was conducted on all children who attended the clinic between September 16, 2009 and November 11, 2013. Propranolol was administered in a progressive schedule reaching 1.0‑1.5 mg/kg/day, divided into three doses. Demographic data, clinical features, imaging, treatment regimens and outcomes were investigated. Any adverse effects following medication were evaluated and managed accordingly. Preliminary analysis of the data showed the inclusion of 106 children (71 female and 35 male) with a mean age and weight at onset of treatment of 5.1 months and 7.3 kg, respectively. All 106 patients responded positively to treatment. Side effects that required intervention and/or close monitoring included diarrhea (n=10), hypotension (n=7), nightmares (n=2), agitation (n=1) and cold extremities (n=1). No long‑term adverse effects were observed in any of the patients. In conclusion, propranolol administered orally at 1.0‑1.5 mg/kg/day had a rapid therapeutic effect for resolving IHs with few complications.

View Figures

View References

1	Frieden IJ, Haggstrom AN, Drolet BA, et al: Infantile hemangiomas: Current knowledge, future directions. In: Proceedings of a research workshop on infantile hemangiomas; April 7–9, 2005; Bethesda. Maryland, USA Pediatr Dermatol. 22:pp. 383–406. 2005
2	Zimmermann AP, Wiegand S, Werner JA and Eivazi B: Propranolol therapy for infantile haemangiomas: Review of the literature. Int J Pediatr Otorhinolaryngol. 74:338–342. 2010. View Article : Google Scholar : PubMed/NCBI
3	Eivazi B, Ardelean M, Bäumler W, et al: Update on hemangiomas and vascular malformations of the head and neck. Eur Arch Otorhinolaryngol. 266:187–197. 2009. View Article : Google Scholar : PubMed/NCBI
4	Werner JA, Dünne AA, Lippert BM and Folz BJ: Optimal treatment of vascular birthmarks. Am J Clin Dermatol. 4:745–756. 2003. View Article : Google Scholar : PubMed/NCBI
5	Amer TA, Elwakil TF and Elbasiouny MS: Open rhinoplasty for treatment of nasal tip haemangioma. Eur J Plast Surg. 30:67–73. 2007. View Article : Google Scholar
6	Kono T, Sakurai H, Groff WF, et al: Comparison study of a traditional pulsed dye laser versus a long-pulsed dye laser in the treatment of early childhood hemangiomas. Lasers Surg Med. 38:112–115. 2006. View Article : Google Scholar : PubMed/NCBI
7	Marler JJ and Mulliken JB: Current management of hemangiomas and vascular malformations. Clin Plast Surg. 32:99–116. 2005. View Article : Google Scholar : PubMed/NCBI
8	Sans V, de la Roque ED, Berge J, et al: Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics. 124:e423–e431. 2009. View Article : Google Scholar : PubMed/NCBI
9	Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB and Taïeb A: Propranolol for severe hemangiomas of infancy. N Engl J Med. 358:2649–2651. 2008. View Article : Google Scholar : PubMed/NCBI
10	Love JN and Sikka N: Are 1–2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med. 26:309–314. 2004. View Article : Google Scholar : PubMed/NCBI
11	Denoyelle F, Leboulanger N, Enjolras O, Harris R, Roger G and Garabedian EN: Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol. 73:1168–1172. 2009. View Article : Google Scholar : PubMed/NCBI
12	Holmes WJ, Mishra A, Gorst C and Liew SH: Propranolol as first-line treatment for infantile hemangiomas. Plast Reconstr Surg. 125:420–421. 2010. View Article : Google Scholar : PubMed/NCBI
13	Jephson CG, Manunza F, Syed S, Mills NA, Harper J and Hartley BE: Successful treatment of isolated subglottic haemangioma with propranolol alone. Int J Pediatr Otorhinolaryngol. 73:1821–1823. 2009. View Article : Google Scholar : PubMed/NCBI
14	Michel JL and Patural H: Response to oral propranolol therapy for ulcerated hemangiomas in infancy. Arch Pediatr. 16:1565–1568. 2009.(In French). View Article : Google Scholar : PubMed/NCBI
15	Blei F: Basic science and clinical aspects of vascular anomalies. Curr Opin Pediatr. 17:501–509. 2005. View Article : Google Scholar : PubMed/NCBI
16	Chang MW: Updated classification of hemangiomas and other vascular anomalies. Lymphat Res Biol. 1:259–265. 2003. View Article : Google Scholar : PubMed/NCBI
17	Storch CH and Hoeger PH: Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 163:269–274. 2010. View Article : Google Scholar : PubMed/NCBI
18	Peridis S, Pilgrim G, Athanasopoulos I and Parpounas K: A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol. 75:455–460. 2011. View Article : Google Scholar : PubMed/NCBI
19	Schiestl C, Neuhaus K, Zoller S, et al: Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr. 170:493–501. 2011. View Article : Google Scholar : PubMed/NCBI
20	Holmes WJ, Mishra A, Gorst C and Liew SH: Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 64:445–451. 2011. View Article : Google Scholar : PubMed/NCBI
21	Denoyelle F and Garabédian EN: Propranolol may become first-line treatment in obstructive subglottic infantile hemangiomas. Otolaryngol Head Neck Surg. 142:463–464. 2010. View Article : Google Scholar : PubMed/NCBI
22	de Graaf M, Breur JM, Raphaël MF, Vos M, Breugem CC and Pasmans SG: Adverse effects of propranolol when used in the treatment of hemangiomas: A case series of 28 infants. J Am Acad Dermatol. 65:320–327. 2011. View Article : Google Scholar : PubMed/NCBI
23	Xiao Q, Li Q, Zhang B and Yu W: Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. Pediatr Surg Int. 29:575–581. 2013. View Article : Google Scholar : PubMed/NCBI
24	Szychta P, Stewart K and Anderson W: Treatment of infantile hemangiomas with propranolol: clinical guidelines. Plast Reconstr Surg. 133:852–862. 2014. View Article : Google Scholar : PubMed/NCBI
25	Chang LC, Haggstrom AN, Drolet BA, et al: Growth characteristics of infantile hemangiomas: Implications for management. Pediatrics. 122:360–367. 2008. View Article : Google Scholar : PubMed/NCBI
26	Kim HJ, Colombo M and Frieden IJ: Ulcerated hemangiomas: Clinical characteristics and response to therapy. J Am Acad Dermatol. 44:962–972. 2001. View Article : Google Scholar : PubMed/NCBI
27	Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y and Richter GT: Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center. Laryngoscope. 120:676–681. 2010. View Article : Google Scholar : PubMed/NCBI